SII Chief Executive Officer Adar Poonawalla told NDTV that the vaccine is being developed in collaboration with Novavax. Poonawalla further...

SII Chief Executive Adar Poonawalla said he was meeting some African officials in Davos to discuss his plans. Asked about possible investme...

In an interview to ET in October, SII chief executive Adar Poonawalla said that large exports would start from January, whereas small expor...

The drug regulator had earlier asked the company - which had applied for emergency use authorisation (SII) for Covovax in August - to submi...

The deal with Serum Institute Life Sciences values Biocon Biologics at about $4.9 billion and will solely focus on COVID-19 vaccines in the...

Poonawalla said SII has applied to the European Medicines Agency (EMA) through AstraZeneca. "The process has to take its time. An approval ...

The SII, which is India's largest vaccine manufacturer, had earlier priced Covishield at Rs 400 per dose for the state governments and Rs 6...

Bharat Biotech on Saturday said it has priced Covaxin at ₹1,200 ($16) for the private market, while the Russian Development Investment Fund...

India, where infections have surged to 13.06 million, suspended all major exports of vaccines last month to fill demand at home, forcing th...

SII chief Adar Poonawalla wrote to Brazil, Morocco and Saudi Arabia that there would be an unspecified delay in sending vaccines that have ...

AstraZeneca has been embroiled in a dispute in Europe after it said it would have to cut supplies of its vaccine there in the first quarter.

SII, the world's biggest vaccine manufacturer, has partnered with AstraZeneca, the Gates Foundation and the Gavi vaccine alliance to make u...

Apart from financial loss, the mishap will impact the production of BCG and Rotavirus vaccines, the company said in a statement.

The chief minister visited the SII on Friday to take stock of the damages. He later addressed a press conference, where Adar Poonawalla, Ch...

The building where the fire broke out is part of the under-construction site of the Serum facility and is one km from the Covishield manufa...

SII has partnered with global pharma giant AstraZeneca and Oxford University for the vaccine candidate 'Covidshield'. "As of now we don't h...

Serum said it has enrolled 1,600 participants in India for late-stage trials of AstraZeneca's candidate, and also plans to seek regulatory ...